Format

Send to

Choose Destination
Breast. 2014 Dec;23(6):816-20. doi: 10.1016/j.breast.2014.08.015. Epub 2014 Sep 26.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Author information

1
Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.
2
Institut Curie, Hospital, Biostatistic Department, 75005 Paris, France.
3
Institut Curie, Hospital, Oncology Department, 75005 Paris, France.
4
CHU Jean Minjoz, Radiotherapy Department, 25030 Besançon, France.
5
Institut régional du Cancer de Montpellier, Radiotherapy Department, 34298 Montpellier, France.
6
Institut Curie, Hospital, Radiotherapy Department, 92210 Saint Cloud, France.
7
Centre d'Oncologie de Gentilly, Radiotherapy Department, 54 100 Nancy, France.
8
Centre Henri Becquerel, Radiotherapy Department, 76038 Rouen, France.
9
Centre François Baclesse, Radiotherapy Department, 14000 Caen, France.
10
Centre Georges-François Leclerc, Département de radiothérapie, 21000 Dijon, France.
11
CHU Tours, Service de cancérologie, 37044 Tours, France.
12
Centre Jean Bernard, Département de radiothérapie, 72000 Le Mans, France.
13
Roche, France.
14
Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.

Abstract

The purpose of this multicenter prospective and descriptive study was to determine late toxicities and outcomes among patients with non-metastatic breast cancer receiving concurrent bevacizumab (BV) and radiation therapy (RT) in the clinical trials. Early and late toxicities were assessed and evaluation was available for 63 patients (pts) at 12 months. Acute radiation dermatitis was observed in 48 (76%): grade 1 for 27, grade 2 for 17 and grade 3 for 4 pts. Grade 2 acute oesophagitis was observed in one patient (2%). Little toxicity was described 1 year after the completion of RT: 7 pts (12%): grade 1-2 pain, 3 (5%) presented grade 1 fibrosis, and 2 pts (4%) - telangiectasia. One patient (2%) experienced grade 1 dyspnoea. Five grade 1-2 lymphoedema occurred. Only one patient experienced a LEVF value less than 50% one year after the end of RT. In conclusion, the concurrent BV with locoregional RT provides acceptable toxicities.

KEYWORDS:

Breast cancer; Concurrent bevacizumab; Radiotherapy

PMID:
25260760
DOI:
10.1016/j.breast.2014.08.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center